Business Monitor International


Qatar Pharmaceuticals & Healthcare Report

Published 20 March 2014

  • 97 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Qatar Pharmaceuticals & Healthcare Report

BMI View: Medicine prices are expected to decline shortly in Qatar amid the 'imminent' unification of medicine importation channels and the adoption of a new medicine pricing mechanism by the member countries of the Gulf Co-operation Council (GCC). The unified regional pharmaceutical pricing policy among GCC member states will reduce medicine prices in Qatar and improve its national drug accessibility, if implemented properly. Although the drug pricing controls can potentially negatively affect multinationals' revenues in the country, increasing volume sales will at least partially offset the effect. As massive hydrocarbon wealth is spread generously across the country's native population, Qatar's pharmaceutical market will remain attractive to multinationals.

Headline Expenditure Projections

  • Pharmaceuticals: QAR1.63bn (USD449mn) in 2013 to QAR1.82bn (USD499mn) in 2014; +11.3% in local currency and 11.3% in US dollar terms. Forecast in line with Q 2 14 .

  • Healthcare: QAR16.75bn (USD4.60bn) in 2013 to QAR18.70bn (USD5.14bn) in 2014; +11.7% in both local currency and US dollar terms. Forecast revised upwards due to macroeconomic modifications.

Risk/Reward Rating: Qatar's risks are particularly low in comparison with the rest of the MEA region, although its potential rewards are dampened by the small market size. Nevertheless, Qatar's high level of urbanisation, rapid population growth and rising prevalence of chronic lifestyle diseases creates an environment in which there is strong potential for market growth. On account of shifts within BMI's Pharmaceutical Risk/Reward Rating Index for the Middle East and Africa matrix, in Q314, Qatar has moved up again one position in the MEA matrix to reclaim fifth place with the country's scores higher this quarter scoring 53.5 out of 100.

Key Trends And Developments

  • In May 2014, Qatar Airways Cargo's India focus continues with the company launching a new weekly freighter service between the airline's hubs in Doha...

Table of Contents

BMI Industry View
7
SWOT
10
Political SWOT
12
Economic SWOT
13
Business Environment SWOT
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Qatar 2010-2018)
20
Healthcare Market Forecast
20
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2010-2018)
22
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2010-2018)
23
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2010-2018)
23
Prescription Drug Market Forecast
24
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Qatar 2010-2018)
25
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Qatar 2010-2018)
26
Generic Drug
27
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Qatar 2010-2018)
28
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Qatar 2010-2018)
30
Pharmaceutical Trade Forecast
30
Table: Pharmaceutical Trade Data And Forecasts (Qatar 2012-2018)
32
Table: Pharmaceutical Trade Data And Forecasts local currency (Qatar 2012-2018)
32
Other Healthcare Data
32
Table: Healthcare Professionals (2009)
33
Key Risks To BMI's Forecast Scenario
34
Macroeconomic Forecasts
36
Economic Analysis
36
Industry Risk Reward Ratings
46
Middle East & Africa Risk/Reward Ratings
46
Qatar Risk/Reward Ratings
54
Rewards
54
Risks
55
Market Overview
56
Industry Trends And Developments
58
Epidemiology
58
Healthcare Sector
63
Healthcare Sector Developments
64
Health Insurance
67
Healthcare IT
68
Research & Development
69
Clinical Trials
71
Regulatory Development
72
Regional Regulatory Developments
73
Intellectual Property Regime
76
Pricing And Reimbursement Regime
76
Competitive Landscape
79
Pharmaceutical Industry
79
Pharmaceutical Wholesale And Retail
80
Company Profile
82
Medicare Group
82
Ebn Sina Medical
84
Qatar Pharma
86
Novartis
88
Merck & Co
90
GlaxoSmithKline
92
Pfizer
94
Demographic Forecast
96
Table: Qatar's Population By Age Group, 1990-2020 ('000)
97
Table: Qatar's Population By Age Group, 1990-2020 (% of total)
98
Table: Qatar's Key Population Ratios, 1990-2020
99
Table: Qatar's Rural And Urban Population, 1990-2020
99
Glossary
100
Methodology
102
Pharmaceutical Expenditure Forecast Model
102
Healthcare Expenditure Forecast Model
102
Notes On Methodology
103
Risk/Reward Ratings Methodology
104
Ratings Overview
105
Table: Pharmaceutical Risk/Reward Ratings Indicators
105
Indicator Weightings
106

The Qatar Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Qatar Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Qatari pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Qatar to test other views - a key input for successful budgeting and strategic business planning in the Qatari pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Qatari pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Qatar.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc